Answers are grounded in this paper and cite their sources.
Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to reduce autoantibodies leading to clinical and radiographic improvement in infection.
No takes yet. Share an insight, caveat, or question.
Rocco et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: